Skip to content
The Nexus
DossierENTITY

GLP-1 Bridge

Coverage of GLP-1 Bridge in the Nexus archive.

Earliest in view: Jun 1 · 08:30 UTCMost recent: Jul 18 · 16:00 UTC
Co-mentioned in this coverage
MedPage Todayorganization1electronic medical recordtopic1Dr. Ozperson1price controlstopic1consumerstopic1Medicareorganization1Wegovytopic1Zepboundtopic1Eli Lillyorganization1Novo Nordiskorganization1Trump administrationorganization1
Recent coverage
  • HEALTHJul 18 · 16:00 UTCMEDPAGE TODAY
    The Upside-Down World of the GLP-1 Bridge

    A healthcare professional examines electronic medical records to investigate the GLP-1 Bridge, focusing on patient data without immediate life-threatening concerns.

  • HEALTHJun 28 · 14:00 UTCTHE HILL
    Dr. Oz’s GLP-1 Bridge could work, but it isn’t a model for price controls

    Dr. Oz’s GLP-1 Bridge may be effective but is not a viable model for price controls. The article warns that consumer discounts today could hinder future medical advancements.

  • HEALTHJun 1 · 08:30 UTCSTAT NEWS
    STAT+: Medicare still won’t say how much covering obesity drugs will cost

    Medicare will cover Wegovy and Zepbound for weight loss starting July 2024 at $50/month for beneficiaries, but has not disclosed the cost to taxpayers. The temporary 'GLP-1 Bridge' program, running until December 2027, bypasses federal law and shifts most costs to taxpayers. The Trump administration initially planned coverage through Medicare Advantage plans, but insurers opposed due to high costs.